FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: nasdaq:amrn

Sort
E.g., 2013-05-21
E.g., 2013-05-21
Enter a comma separated list of user names.

AMRN, Amarin Corporation plc

** AMRN reported that its New Drug Application for AMR101 has been accepted for filing by the FDA

AMRN is developing AMR101 for the treatment of patients with very high triglyceride levels and as a potentially first-in-class therapy for patients with high triglyceride levels who are also on statin therapy for elevated LDL-cholesterol levels.

Amarin Corporation plc (NASDAQ:AMRN) announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin’s participation includes both a panel discussion on Cardiology at 7:45am ET and a company presentation at 9:15am ET. The conference will be held at the Roosevelt Hotel in New York City.

Amarin Corporation plc (NASDAQ:AMRN) is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate).

Pages

ADVERTISE WITH US